# Jain Dataset - ELISA-based Fragments (SSOT)
# Source: test_datasets/jain/processed/jain_with_private_elisa_FULL.csv
# Labeling: ELISA flags (0→specific, 1-3→mild, ≥4→non-specific)
# Distribution: 94 specific / 22 non-specific / 21 mild
# Generated: 2025-11-06
# Script: preprocessing/jain/step3_extract_fragments.py
id,sequence,label,elisa_flags,source
abituzumab,GYTFSSFWINPRSGYTASFLGRGAMDYQDISNYYTSQQGNTFPYT,0.0,0,jain2017_pnas
abrilumab,GYTLSDLSFDPQDGETATGSSSSWFDPQGISSWGASQQANSFPWT,0.0,0,jain2017_pnas
adalimumab,GFTFDDYAITWNSGHIAKVSYLSTASSLDYQGIRNYAASQRYNRAPYT,0.0,0,jain2017_pnas
alemtuzumab,GFTFTDFYIRDKAKGYTTAREGHTAAPFDYQNIDKYNTNLQHISRPRT,0.0,0,jain2017_pnas
alirocumab,GFTFNNYAISGSGGTTAKDSNWGNFDLQSVLYRSNNRNFWASQQYYTTPYT,0.0,0,jain2017_pnas
anifrolumab,GYIFTNYWIYPGDSDIARHDIEGFDYQSVSSSFGASQQYDSSAIT,0.0,0,jain2017_pnas
atezolizumab,GFTFSDSWISPYGGSTARRHWPGGFDYQDVSTASASQQYLYHPAT,0.0,0,jain2017_pnas
bapineuzumab,GFTFSNYGIRSGGGRTVRYDHYSGSSDYQSLLDSDGKTYLVSWQGTHFPRT,0.0,0,jain2017_pnas
basiliximab,GYSFTRYWIYPGNSDTSRDYGYYFDFSSRSYDTSHQRSSYT,0.0,0,jain2017_pnas
bavituximab,GYSFTGYNIDPYYGDTVKGGYYGHWYFDVQDIGSSATSLQYVSSPPT,0.0,0,jain2017_pnas
belimumab,GGTFNNNAIIPMFGTAARSRDLLLFPHHALSPSLRSYYGKNSSRDSSGNHWV,1.0,6,jain2017_pnas
benralizumab,GYTFTSYVINPYNDGTGREGIRYYGLLGDYEDIINYHTSQQGYTLPYT,0.0,0,jain2017_pnas
bevacizumab,GYTFTNYGINTYTGEPAKYPHYYGSSHWYFDVQDISNYFTSQQYSTVPWT,0.0,0,jain2017_pnas
bimagrumab,GYTFTSSYINPVSGSTARGGWFDYSSDVGSYNYGVSGTFAGGSYYGV,0.0,0,jain2017_pnas
blosozumab,GFPIKDTFSDPEIGDTATGDTTYKFDFQDVHTAWASQQYSDYPWT,1.0,6,jain2017_pnas
bococizumab,GYTFTSYYISPFGGRTARERPLYASDLQGISSASASQQRYSLWRT,1.0,6,jain2017_pnas
brentuximab,GYTFTDYYIYPGSGNTANYGNYWFAYQSVDFDGDSYAASQQSNEDPWT,,3,jain2017_pnas
briakinumab,GFTFSSYGIRYDGSNKKTHGSHDNRSNIGSNTYNDQSYDRYTHPALL,1.0,4,jain2017_pnas
brodalumab,GYTFTRYGISTYSGNTARRQLYFDYQSVSSNDASQQYDNWPLT,,1,jain2017_pnas
canakinumab,GFTFSVYGIWYDGDNQARDLRTGPFDYQSIGSSYASHQSSSLPFT,0.0,0,jain2017_pnas
carlumab,GGTFSSYGIIPIFGTAARYDGIYGELDFQSVSDAYDASHQYIQLHSFT,1.0,4,jain2017_pnas
certolizumab,GYVFTDYGINTYIGEPARGYRSYAMDYQNVGTNSASQQYNIYPLT,0.0,0,jain2017_pnas
cetuximab,GFSLTNYGIWSGGNTARALTYYDYEFAYQSIGTNYASQQNNNWPTT,0.0,0,jain2017_pnas
cixutumumab,GGTFSSYAIIPIFGTAARAPLRFLEWSTQDHYYYYYMDVSLRSYYGENKSRDGSGQHLV,1.0,6,jain2017_pnas
clazakizumab,GFSLSNYYIYGSDETARDDSSDWDAKFNLQSINNERASQQGYSLRNIDNA,0.0,0,jain2017_pnas
codrituzumab,GYTFTDYELDPKTGDTTRFYSYTYQSLVHSNRNTYKVSSQNTHVPPT,1.0,6,jain2017_pnas
crenezumab,GFTFSSYGINSNGGSTASGDYQSLVYSNGDTYKVSSQSTHVPWT,0.0,0,jain2017_pnas
dacetuzumab,GYSFTGYYVIPNAGGTAREGIYWQSLVHSNGNTFTVSSQTTHVPWT,0.0,0,jain2017_pnas
daclizumab,GYTFTSYRINPSTGYTARGGGVFDYSSISYTTSHQRSTYPLT,,1,jain2017_pnas
dalotuzumab,GYSITGGYLISYDGTNARYGRVFFDYQSIVHSNGNTYKVSFQGSHVPWT,1.0,5,jain2017_pnas
daratumumab,GFTFNSFAISGSGGGTAKDKILWFGEPVFDYQSVSSYDASQQRSNWPPT,0.0,0,jain2017_pnas
denosumab,GFTFSSYAITGSGGSTAKDPGTTVIMSWFDPQSVRGRYGASQQYGSSPRT,1.0,5,jain2017_pnas
dinutuximab,GSSFTGYNIDPYYGGTVSGMEYQSLVHRNGNTYKVSSQSTHVPPLT,0.0,0,jain2017_pnas
drozitumab,GFTFDDYAINWQGGSTAKILGAGRGWYFDYSLRSYYGANNSADSSGNHVV,0.0,0,jain2017_pnas
duligotuzumab,GFTLSGDWISAAGGYTARESRVSFEAAMDYQNIATDSASQQSEPEPYT,1.0,6,jain2017_pnas
dupilumab,GFTFRDYAISGSGGNTAKDRLSITIRPRYYGLDVQSLLYSIGYNYLGSMQALQTPYT,1.0,5,jain2017_pnas
eculizumab,GYIFSNYWILPGSGSTARYFFGSSPNWYFDVENIYGAGATQNVLNTPLT,0.0,0,jain2017_pnas
efalizumab,GYSFTGHWIHPSDSETARGIYFYGTTYFDYKTISKYSGSQQHNEYPLT,0.0,0,jain2017_pnas
eldelumab,GFTFSNNGIWFDGMNKAREGDGSGIYYYYGMDVQSVSSSYGASQQYGSSPIFT,0.0,0,jain2017_pnas
elotuzumab,GFDFSRYWINPDSSTIARPDGNYWYFDVQDVGIAWASQQYSSYPYT,0.0,0,jain2017_pnas
emibetuzumab,GYTFTDYYVNPNRRGTARANWLDYSSVSSIYSTSQVYSGYPLT,1.0,6,jain2017_pnas
enokizumab,GGTFSYYWILPGSGTTARADYYGSDYVKFDYQHVITHGTSQQFYEYPLT,0.0,0,jain2017_pnas
epratuzumab,GYTFTSYWINPRNDYTARRDITTFYQSVLYSANHKNYWASHQYLSSWT,,1,jain2017_pnas
etrolizumab,GFFITNNYISYSGSTARTGSSGYFDFESVDDLYASQQGNSLPNT,,2,jain2017_pnas
evolocumab,GYTLTSYGVSFYNGNTARGYGMDVSSDVGGYNSEVSNSYTSTSMV,,2,jain2017_pnas
farletuzumab,GFTFSGYGISSGGSYTARHGDDPAWFAYSSISSNNGTSQQWSSYPYMYT,0.0,0,jain2017_pnas
fasinumab,GFTLTELSFDPEDGETSTIFGVVTNFDNQAIRNDAAFQQYNRYPWT,0.0,0,jain2017_pnas
fezakinumab,GYTFTNYYINPYTGSAAREPEKFDSDDSDVSSNIGAGYGGDSQSYDNSLSGYV,0.0,0,jain2017_pnas
ficlatuzumab,GYTFTTYWINPTNGHTARNYVGSIFDYENVVSYGASGQSYNYPYT,0.0,0,jain2017_pnas
figitumumab,GFTFSSYAISGSGGTTAKDLGWSDSYYYYYGMDVQGIRNDAASLQHNSYPCS,,3,jain2017_pnas
fletikumab,GYTFTNDIINAGYGNTAREPLWFGESSPHDYYGMDVQGISSADASQQFNSYPLT,0.0,0,jain2017_pnas
foralumab,GFKFSGYGIWYDGSKKARQMGYWHFDLQSVSSYDASQQRSNWPPLT,,2,jain2017_pnas
fresolimumab,GYTFSSNVVIPIVDIAASTLGLVLDAMDYQSLGSSYGASQQYADSPIT,0.0,0,jain2017_pnas
fulranumab,GFTLRSYSISRSSHTIARVYSSGWHVSDYFDYQGISSADASQQFNSYPLT,,1,jain2017_pnas
galiximab,GGSISGGYGFYSSSGNTVRDRLFSVVGMVYNNWFDVTSNIGGYDDINQSYDSSLNAQV,0.0,0,jain2017_pnas
ganitumab,GGSISSSNWIYHSGSTARWTGRTDAFDIQSLLHSNGYNYLGSMQGTHWPLT,0.0,0,jain2017_pnas
gantenerumab,GFTFSSYAINASGTRTARGKGNTHKPYGYVRYFDVQSVSSSYGASLQIYNMPIT,1.0,6,jain2017_pnas
gemtuzumab,GYTITDSNIYPYNGGTVNGNPWLAYESLDNYGIRFAASQQTKEVPWS,0.0,0,jain2017_pnas
gevokizumab,GFSLSTSGMGIWWDGDEARNRYDPPWFVDQDISNYYTSLQGKMLPWT,0.0,0,jain2017_pnas
girentuximab,GFTFSNYYINSDGGITARHRSGYFSMDYQNVVSASASQQYSNYPWT,0.0,0,jain2017_pnas
glembatumumab,GGSISSFNYYIYYSGSTARGYNWNYFDYQSVDNNGASQQYNNWPPWT,0.0,0,jain2017_pnas
golimumab,GFIFSSYAMSYDGSNKARDRGIAAGGNYYYYGMDVQSVYSYDASQQRSNWPPFT,,1,jain2017_pnas
guselkumab,GYSFSNYWIDPSNSYTARWYYKPFDVSSNIGSGYDGNSASWTDGLSLVV,,1,jain2017_pnas
ibalizumab,GYTFTSYVINPYNDGTAREKDNYATGAWFAYQSLLYSTNQKNYWASQQYYSYRT,0.0,0,jain2017_pnas
imgatuzumab,GFTFTDYKFNPNSGYSARLSPGGYYVMDAQGINNYNTNLQHNSFPT,1.0,5,jain2017_pnas
infliximab,GFIFSNHWIRSKSINSATSRNYYGSTYDYQFVGSSYASQQSHSWPFT,0.0,0,jain2017_pnas
inotuzumab,GYRFTNYWINPGNNYATREGYGNYGAWFAYQSLANSYGNTFGISLQGTHQPYT,,3,jain2017_pnas
ipilimumab,GFTFSSYTISYDGNNKARTGWLGPFDYQSVGSSYGAFQQYGSSPWT,0.0,0,jain2017_pnas
ixekizumab,GYSFTDYHINPMYGTTARYDYFTGTGVYRSLVHSRGNTYKVSSQSTHLPFT,1.0,6,jain2017_pnas
lampalizumab,GYTFTNYGINTYTGETEREGGVNNTDIDDDGGNLQSDSLPYT,0.0,0,jain2017_pnas
lebrikizumab,GFSLSAYSIWGDGKIAGDGYYPYAMDNKSVDSYGNSFLASQQNNEDPRT,0.0,0,jain2017_pnas
lenzilumab,GYSFTNYYINAGNGNTVRRQRFPYYFDYQSVGTNSTSQQFNKSPLT,1.0,6,jain2017_pnas
lintuzumab,GYTFTDYNIYPYNGGTARGRPAMDYESVDNYGISFAASQQSKEVPWT,0.0,0,jain2017_pnas
lirilumab,GGTFSFYAFIPIFGAAARIPSGSYYYDYDMDVQSVSSYDASQQRSNWMYT,0.0,0,jain2017_pnas
lumiliximab,GFRFTFNNYYISSSGDPTASLTTGSDSQDIRYYVASLQVYSTPRT,0.0,0,jain2017_pnas
matuzumab,GYTFTSHWFNPSNGRTASRDYDYDGRYFDYSSVTYDTSQQWSSHIFT,0.0,0,jain2017_pnas
mavrilimumab,GYTLTELSFDPEENEIAIVGSFSPLTLGLGSNIGAPYDHNNATVEAGLSGSV,0.0,0,jain2017_pnas
mepolizumab,GFSLTSYSIWASGGTARDPPSSLLRLDYQSLLNSGNQKNYGASQNVHSFPFT,0.0,0,jain2017_pnas
mogamulizumab,GFIFSNYGISSASTYSGRHSDGNFAFGYRNIVHINGDTYKVSFQGSLLPWT,0.0,0,jain2017_pnas
motavizumab,GFSLSTAGMSIWWDDKKARDMIFNFYFDVSRVGYDTSFQGSGYPFT,,1,jain2017_pnas
muromonab,GYTFTRYTINPSRGYTARYYDDHYCLDYSSVSYDTSQQWSSNPFT,0.0,0,jain2017_pnas
natalizumab,GFNIKDTYIDPANGYTAREGYYGNYGVYAMDYQDINKYYTSLQYDNLWT,0.0,0,jain2017_pnas
necitumumab,GGSISSGDYYIYYSGSTARVSIFGVGTFDYQSVSSYDASHQYGSTPLT,0.0,0,jain2017_pnas
nimotuzumab,GYTFTNYYINPTSGGSTRQGLWFDSDGRGFDFQNIVHSNGNTYKVSFQYSHVPWT,0.0,0,jain2017_pnas
nivolumab,GITFSNSGIWYDGSKRATNDDYQSVSSYDASQQSSNWPRT,0.0,0,jain2017_pnas
obinutuzumab,GYAFSYSWIFPGDGDTARNVFDGYWLVYKSLLHSNGITYQMSAQNLELPYT,0.0,0,jain2017_pnas
ocrelizumab,GYTFTSYNIYPGNGDTARVVYYSNSYWYFDVSSVSYAPSQQWSFNPPT,0.0,0,jain2017_pnas
ofatumumab,GFTFNDYAISWNSGSIAKDIQYGNYYYGMDVQSVSSYDASQQRSNWPIT,0.0,0,jain2017_pnas
olaratumab,GGSINSSSYYFFYTGSTARQSTYYYGSGNYYGWFDRQSVSSYDASQQRSNWPPA,0.0,0,jain2017_pnas
olokizumab,GFNFNDYFMRNKNYQYGTARESYYGFTSYQDIGISNANLQHNSAPYT,0.0,0,jain2017_pnas
omalizumab,GYSITSGYSITYDGSTARGSHYFGHWHFAVQSVDYDGDSYAASQQSHEDPYT,0.0,0,jain2017_pnas
onartuzumab,GYTFTSYWIDPSNSDTATYRSYVTPLDYQSLLYTSSQKNYWASQQYYAYPWT,0.0,0,jain2017_pnas
otelixizumab,GFTFSSFPISTSGGRTAKFRQYSGGFDYSGNIENNYDDDHSYVSSFNV,0.0,0,jain2017_pnas
otlertuzumab,GYSFTGYNIDPYYGGTARSVGPFDSENVYSYFAKQHHSDNPWT,0.0,0,jain2017_pnas
ozanezumab,GYTFTSYWINPSNGGTELMQGYKSLLYKDGKTYLMSQQLVEYPLT,,3,jain2017_pnas
palivizumab,GFSLSTSGMSIWWDDKKARSMITNWYFDVLSVGYDTSFQGSGYPFT,0.0,0,jain2017_pnas
panitumumab,GGSVSSGDYYIYYSGNTVRDRVTGAFDIQDISNYDASQHFDHLPLA,0.0,0,jain2017_pnas
panobacumab,GFTFSPYWINSDGSTARDRYYGPEMQSLVYSDGNTYKVSMQGTHWPLT,0.0,0,jain2017_pnas
parsatuzumab,GYTFIDYYINLDNSGTAREGVYHDYDDYAMDYQSLVHINAITYRVSGQSTHVPLT,1.0,6,jain2017_pnas
patritumab,GGSFSGYYINHSGSTARDKWTWYFDLQSVLYSSSNRNYWASQQYYSTPRT,1.0,4,jain2017_pnas
pembrolizumab,GYTFTNYYINPSNGGTARRDYRFDMGFDYKGVSTSGYSYLASQHSRDLPLT,0.0,0,jain2017_pnas
pertuzumab,GFTFTDYTVNPNSGGSARNLGPSFYFDQDVSIGSASQQYYIYPYT,0.0,0,jain2017_pnas
pinatuzumab,GYEFSRSWIYPGDGDTARDGSSWDWYFDVQSIVHSVGNTFKVSFQGSQFPYT,0.0,0,jain2017_pnas
polatuzumab,GYTFSSYWILPGGGDTTRRVPIRLDYQSVDYEGDSFAASQQSNEDPLT,0.0,0,jain2017_pnas
ponezumab,GYYTEAYYIDPATGNTASLYSLPVYQSLLYSDAKTYQISLQGTHYPVL,1.0,4,jain2017_pnas
radretumab,GFTFSSFSISGSSGTTAKPFPYFDYQSVSSSFYASQQTGRIPPT,0.0,0,jain2017_pnas
ramucirumab,GFTFSSYSISSSSSYIARVTDAFDIQGIDNWDASQQAKAFPPT,0.0,0,jain2017_pnas
ranibizumab,GYDFTHYGINTYTGEPAKYPYYYGTSHWYFDVQDISNYFTSQQYSTVPWT,,1,jain2017_pnas
reslizumab,GLSLTSNSIWSNGDTAREYYGYFDYEGISSYGANQQSYKFPNT,0.0,0,jain2017_pnas
rilotumumab,GGSISIYYVYYSGSTARGGYDFWSGYFDYQSVDSNGASQQYINWPPIT,0.0,0,jain2017_pnas
rituximab,GYTFTSYNIYPGNGDTARSTYYGGDWYFNVSSVSYATSQQWTSNPPT,0.0,0,jain2017_pnas
robatumumab,GFTFSSFAIDTRGATARLGNFYYGMDVQSIGSSYASHQSSRLPHT,1.0,4,jain2017_pnas
romosozumab,GYTFTDYNINPNSGGAARLGYDDIYDDWYFDVQDISNYYTSQQGDTLPYT,0.0,0,jain2017_pnas
sarilumab,RFTFDDYAISWNSGRIAKGRDSFDIQGISSWGASQQANSFPYT,0.0,0,jain2017_pnas
secukinumab,GFTFSNYWINQDGSEKVRDYYDILTDYYIHYWYFDLQSVSSSYGASQQYGSSPCT,0.0,0,jain2017_pnas
seribantumab,GFTFSHYVISSSGGWTTRGLKMATIFDYSSDVGSYNVEVSCSYAGSSIFVI,0.0,0,jain2017_pnas
sifalimumab,GYTFTSYSISVYNGNTARDPIAAGYQSVSSTYGASQQYGSSPRT,,3,jain2017_pnas
siltuximab,GFTFSSFAISSGGSYTARGLWGYYALDYSSVSYDTSQQWSGYPYT,0.0,0,jain2017_pnas
simtuzumab,GYAFTYYLINPGSGGTARNWMNFDYKSLLHSNGNTYRMSMQHLEYPYT,1.0,6,jain2017_pnas
sirukumab,GFTFSPFAISPGGSWTARQLWGYYALDIISVSYDMSMQWSGYPYT,1.0,5,jain2017_pnas
tabalumab,GGSFSGYYINHSGSTARGYYDILTGYYYYFDYQSVSRYDASQQRSNWPRT,0.0,0,jain2017_pnas
tanezumab,GFSLIGYDIWGDGTTARGGYWYATSYYFDYQSISNNYTSQQEHTLPYT,,1,jain2017_pnas
teplizumab,GYTFTRYTINPSRGYTARYYDDHYCLDYSSVSYDTSQQWSSNPFT,,2,jain2017_pnas
tigatuzumab,GFTFSSYVISSGGSYTARRGDSMITTDYQDVGTAWASQQYSSYRT,0.0,0,jain2017_pnas
tildrakizumab,GYIFITYWIFPASGSAARGGGGFAYENIYSYNAKQHHYGIPFT,0.0,0,jain2017_pnas
tocilizumab,GYSITSDHAISYSGITARSLARTTAMDYQDISSYYTSQQGNTLPYT,0.0,0,jain2017_pnas
tovetumab,GFTFSDYYISSSGSIIAREGRIAARGMDVQSFSRYAASQQTYSNPPIT,0.0,0,jain2017_pnas
tralokinumab,GYTFTNYGISANNGDTARDSSSSWARWFFDLIIGSKLDDGQVWDTGSDPVV,0.0,0,jain2017_pnas
trastuzumab,GFNIKDTYIYPTNGYTSRWGGDGFYAMDYQDVNTASASQQHYTTPPT,0.0,0,jain2017_pnas
tremelimumab,GFTFSSYGIWYDGSNKARDPRGATLYYYYYGMDVQSINSYAASQQYYSTPFT,0.0,0,jain2017_pnas
urelumab,GGSFSGYYINHGGYVARDYGPGNYDWYFDLQSVSSYDASQQRSNWPPALT,0.0,0,jain2017_pnas
ustekinumab,GYSFTTYWMSPVDSDIARRRPGQGYFDFQGISSWAASQQYNIYPYT,,3,jain2017_pnas
vedolizumab,GYTFTSYWIDPSESNTARGGYDGWDYAIDYQSLAKSYGNTYGISLQGTHQPYT,0.0,0,jain2017_pnas
veltuzumab,GYTFTSYNIYPGMGDTARSTYYGGDWYFDVSSVSYATSQQWTSNPPT,0.0,0,jain2017_pnas
visilizumab,GYTFISYTINPRSGYTARSAYYDYDGFAYSSVSYDTSQQWSSNPPT,,3,jain2017_pnas
zalutumumab,GFTFSTYGIWDDGSYKARDGITMVRGVMKDYFDYQDISSADASQQFNSYPLT,,1,jain2017_pnas
zanolimumab,GGSFSGYYINHSGSTARVINWFDPQDISSWAASQQANSFPYT,0.0,0,jain2017_pnas
